types of glp 1 receptor agonists drugs GLP-1 Agonists: An Alternative for Rapid-Acting Insulin? Classification of currently available glucagon-like
Description
Antes de registrarte, revisa la letra pequea y define tu presupuesto mximo, de modo que la diversin siga siendo el centro de la experiencia y no un motivo de preocupacin
Why the hype: Diabetes, obesity, and vascular disease are known contributors to brain aging and dementia risk
The news: People who stop using GLP-1 weight loss drugs regain weight rapidly and lose most of the health benefits they had gained in less than two years, according to Oxford University analysis of 37 clinical studies involving more than 9,300 participants published recently
The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
This stands in contrast to the hepatotoxicity that terminated Pfizer's danuglipron and lotiglipron programs
